ERBB2 and cancer: Luminal B, HER2-enriched, and TNBC have poorer clinical outcomes compared to luminal A. With the advent of transcriptomic methods, there is an increasing interest in identifying unique marker panels, from blood and tissue that can establish cancer subtypes leading to treatment recommendations.